Javascript must be enabled to continue!
Are sex and gender dimensions accounted for in NICE guidelines? A systematic review of 223 clinical guidelines
View through CrossRef
Introduction
The importance of sex and gender in the diagnosis and management of health conditions is well established, but the extent to which sex and gender disaggregated evidence is integrated into UK clinical practice guidelines remains unknown. Recent reviews of clinical guidelines in Canada and Europe identified that limited and inconsistent attention was paid to sex and gender dimensions of health and illness. This study aimed to determine how the UK’s National Institute of Clinical Excellence (NICE) clinical guidelines account for sex and gender.
Methods
The study reviewed all NICE guidelines categorised as ‘clinical guidelines’ by NICE (223), excluding those solely linked to single-sex conditions (26). Reviewers evaluated whether they included information on sex and/or gender dimensions of disease risk, presentation, investigations and management. They also examined if sex and/or gender dimensions were considered outside of pregnancy, and how the gender of guideline committee chairs and members corresponded to how well sex and/or gender were accounted for.
Results
Of 197 guidelines reviewed, 120 (61%) referenced sex and/or gender dimensions, with 81 (41%) referencing these dimensions outside of pregnancy and childbearing. A minority of guidelines mentioned sex and/or gender dimensions related to disease pathophysiology (2%), clinical presentation (9%), investigations (15%) and epidemiology (19%). 162 guidelines published details of their committee chairs, and 126 (76%) were men. Committees chaired by women tended to produce guidelines, which scored better for consideration of sex and gender.
Conclusion
This study highlights key gaps in NICE guidelines which must be addressed through systematic, whole-sector progress to integrate sex and gender disaggregated research into clinical guidelines. As the single focal point responsible for guideline development in England and Wales, NICE has a unique opportunity to establish robust mechanisms to routinely embed this important evidence in guidelines. Multiple initiatives are recommended to identify relevant existing evidence across all clinical specialties.
Title: Are sex and gender dimensions accounted for in NICE guidelines? A systematic review of 223 clinical guidelines
Description:
Introduction
The importance of sex and gender in the diagnosis and management of health conditions is well established, but the extent to which sex and gender disaggregated evidence is integrated into UK clinical practice guidelines remains unknown.
Recent reviews of clinical guidelines in Canada and Europe identified that limited and inconsistent attention was paid to sex and gender dimensions of health and illness.
This study aimed to determine how the UK’s National Institute of Clinical Excellence (NICE) clinical guidelines account for sex and gender.
Methods
The study reviewed all NICE guidelines categorised as ‘clinical guidelines’ by NICE (223), excluding those solely linked to single-sex conditions (26).
Reviewers evaluated whether they included information on sex and/or gender dimensions of disease risk, presentation, investigations and management.
They also examined if sex and/or gender dimensions were considered outside of pregnancy, and how the gender of guideline committee chairs and members corresponded to how well sex and/or gender were accounted for.
Results
Of 197 guidelines reviewed, 120 (61%) referenced sex and/or gender dimensions, with 81 (41%) referencing these dimensions outside of pregnancy and childbearing.
A minority of guidelines mentioned sex and/or gender dimensions related to disease pathophysiology (2%), clinical presentation (9%), investigations (15%) and epidemiology (19%).
162 guidelines published details of their committee chairs, and 126 (76%) were men.
Committees chaired by women tended to produce guidelines, which scored better for consideration of sex and gender.
Conclusion
This study highlights key gaps in NICE guidelines which must be addressed through systematic, whole-sector progress to integrate sex and gender disaggregated research into clinical guidelines.
As the single focal point responsible for guideline development in England and Wales, NICE has a unique opportunity to establish robust mechanisms to routinely embed this important evidence in guidelines.
Multiple initiatives are recommended to identify relevant existing evidence across all clinical specialties.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Selvitystä astevaihteluun
Selvitystä astevaihteluun
KielenaineksetAkedolæ (kieli: viro, sivulla: 223)Annikvere (kieli: viro, sivulla: 226)Attol(a) (kieli: viro, sivulla: 223)Hag|edell, -geda (kieli: viro, sivulla: 223)Hirla (kieli: ...
Effect of miR-223-3p on cell pyroptosis in myelodysplastic syndrome and its
mechanism via regulating the expression of NLRP3
Effect of miR-223-3p on cell pyroptosis in myelodysplastic syndrome and its
mechanism via regulating the expression of NLRP3
This study aimed to investigate the regulatory mechanism of the miR-223-3p/NLRP3 signaling axis in
the progression of myelodysplastic syndrome (MDS). For this purpose, SKM-1 cells ...
Re-treatment of metastatic castration-resistant prostate cancer patients with radium-223 therapy in daily practice.
Re-treatment of metastatic castration-resistant prostate cancer patients with radium-223 therapy in daily practice.
183
Background:
Radium-223 is a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomat...
MicroRNA-223 prevents cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase
MicroRNA-223 prevents cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase
Objectives
Our study was designed to investigate the role of microRNA-223 (miR-223) and its direct target gene, cardiac troponin I-interacting kinase (TNNI3K), in...
Patient characteristics and safety of radium-223 dichloride in Taiwan: Analysis of real-world clinical practice.
Patient characteristics and safety of radium-223 dichloride in Taiwan: Analysis of real-world clinical practice.
119 Background: Bone metastases commonly develop in patients with metastatic castration-resistant prostate cancer (mCRPC), leading to poor clinical outcomes. Radium-223 (Ra-223) i...
#2033 Patient characteristics and outcomes of an inter- and multidisciplinary nephrology and cardiology clinic
#2033 Patient characteristics and outcomes of an inter- and multidisciplinary nephrology and cardiology clinic
Abstract
Background and Aims
The prevalence of cardiorenal syndrome is increasing due to the growing number of patients with chr...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...

